ZyVersa Therapeutics, Inc. (ZVSA)
ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a cholesterol efflux modulator aimed at addressing kidney diseases such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease. Furthermore, ZyVersa is advancing IC 100, a pioneering inflammasome ASC inhibitor positioned to tackle a wide array of inflammatory conditions. The company maintains its corporate headquarters in Weston, Florida.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
ZyVersa Therapeutics, Inc.
- 1.7%
- 138.4K
- 238.20
Float 8.09M · Signal8 dilution snapshot · May 13, 2026
The cost to borrow ZVSA shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- 86.2%
- 1
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
Latest short interest settlements (today's share basis)
| Date | Shares short |
|---|---|
| Oct 30, 2026 | 138.4K sh |
| Oct 15, 2026 | 138.4K sh |
| Sep 30, 2026 | 141.6K sh |
| Sep 15, 2026 | 141.6K sh |
| Aug 31, 2026 | 141.6K sh |
Latest fails to deliver
| Date | Shares failed |
|---|---|
| Aug 4, 2026 | 1 sh |
| Aug 3, 2026 | 1 sh |
| Jul 31, 2026 | 1 sh |
| Jul 30, 2026 | 1 sh |
| Apr 16, 2026 | 1 sh |
A stock split executed inside this window; every settlement plotted has been carried onto today’s share basis, so the line does not step at the split.
The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.
Latest sessions
| Date | Reported short |
|---|---|
| Nov 12, 2026 | 86.2% |
| Nov 11, 2026 | 84.5% |
| Nov 10, 2026 | 0.7% |
| Nov 6, 2026 | 36.6% |
| Nov 5, 2026 | 74.6% |
130 calendar days requested; 25 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.
Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
FINRA's weekly alternative trading system (dark pool) volume for ZVSA: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.
As of the Oct 30, 2026 FINRA settlement, 138,394 ZVSA shares were sold short (1.71% of a 8.09M-share float, 238.20 days to cover).